# DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

> **NCT04845646** · PHASE1 · COMPLETED · sponsor: **Gannex Pharma Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Healthy
- NAFLD

## Interventions

- **DRUG:** ASC41
- **DRUG:** Itraconazole
- **DRUG:** Phenytoin

## Key facts

- **NCT ID:** NCT04845646
- **Lead sponsor:** Gannex Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-16
- **Primary completion:** 2021-06-10
- **Final completion:** 2021-06-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04845646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04845646, "DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04845646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*